PharmaCyte Biotech (PMCB) Price/OCF Ratio: History & Chart

PharmaCyte Biotech, Inc.(PMCB)

Biotechnology · Las Vegas, NV

$0.42+0.03 (+8.28%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About PharmaCyte Biotech, Inc.

PharmaCyte Biotech, Inc. is a biotechnology firm dedicated to the development and commercialization of advanced cellular therapies within the United States. Their primary therapeutic areas include various forms of cancer, diabetes, and malignant ascites. Central to their efforts is Cell-in-a-Box, their proprietary encapsulation technology which utilizes cellulose to enclose live cells. This innovative platform serves as the foundation for treatments aimed at diverse cancers, such as advanced and inoperable pancreatic cancer, as well as diabetes. The company's pipeline includes therapies for pancreatic and other solid cancerous tumors; a treatment for Type 1 and insulin-dependent Type 2 diabetes involving encapsulated, genetically modified insulin-producing cells; and cancer treatments derived from cannabis plant compounds. To further its research, PharmaCyte maintains collaborative agreements: one with the University of Technology, Sydney, for the creation of melligen cells to combat diabetes, and another with the University of Northern Colorado, focusing on methods for identifying, separating, and quantifying cannabis constituents. Originally established in 1996, the company operated under the name Nuvilex, Inc. before rebranding as PharmaCyte Biotech, Inc. in January 2015. Its corporate headquarters are located in Las Vegas, Nevada.

Las Vegas, NV

2 employees

pharmacyte.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Joshua N. Silverman

View full financials

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
PharmaCyte Biotech, Inc. (PMCB)	$4.53M	N/A	N/A	N/A	N/A
Dermata Therapeutics, Inc. (DRMA)vs ›	$4.55M	N/A	N/A	N/A	N/A
CollPlant Biotechnologies Ltd. (CLGN)vs ›	$4.40M	N/A	35.59	35.59	35.59
CalciMedica, Inc. (CALC)vs ›	$4.69M	N/A	N/A	N/A	N/A
Imunon, Inc. (IMNN)vs ›	$4.71M	N/A	15.43	17.34	17.34
Bio Green Med Solution, Inc. (BGMS)vs ›	$4.72M	N/A	N/A	N/A	N/A
20/20 Biolabs Inc. (AIDX)vs ›	$4.32M	N/A	N/A	N/A	N/A
Xenetic Biosciences, Inc. (XBIO)vs ›	$4.86M	N/A	11.16	11.16	11.16
Processa Pharmaceuticals, Inc. (PCSA)vs ›	$4.21M	N/A	N/A	N/A	N/A
GRI Bio, Inc. (GRI)vs ›	$4.15M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PRICE/OCF RATIO

TTM

PharmaCyte Biotech, Inc. (PMCB)

$4.53M

N/A

Dermata Therapeutics, Inc. (DRMA)vs ›

$4.55M

N/A

CollPlant Biotechnologies Ltd. (CLGN)vs ›

$4.40M

N/A

35.59

CalciMedica, Inc. (CALC)vs ›

$4.69M

N/A

Imunon, Inc. (IMNN)vs ›

$4.71M

N/A

15.43

17.34

Bio Green Med Solution, Inc. (BGMS)vs ›

$4.72M

N/A

20/20 Biolabs Inc. (AIDX)vs ›

$4.32M

N/A

Xenetic Biosciences, Inc. (XBIO)vs ›

$4.86M

N/A

11.16

Processa Pharmaceuticals, Inc. (PCSA)vs ›

$4.21M

N/A

GRI Bio, Inc. (GRI)vs ›

$4.15M

N/A

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Price/OCF Ratio: N/A

PMCB Price/OCF Ratio Metrics

PMCB Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics